Nexalin Technology Receives Nasdaq Listing Status Notification

Core Viewpoint - Nexalin Technology, Inc. has received a notification from NASDAQ regarding non-compliance with the minimum bid price requirement for continued listing, specifically under NASDAQ Listing Rule 5550(a)(2) [1][2] Group 1: Compliance Notification - The company is not in compliance with the minimum bid price requirement of US$1.00 per share, as its shares have not met this threshold for 30 consecutive business days [2] - The company has been given 180 calendar days, until July 20, 2026, to regain compliance by achieving a closing bid price of at least US$1.00 for a minimum of 10 consecutive trading days [3] - The receipt of the notification does not immediately affect the trading of the company's shares, which will continue to trade on NASDAQ under the ticker "NXL" [4] Group 2: Company Actions and Future Plans - The company intends to monitor its bid price continuously and is considering various measures to improve its financial position and operational results [4] - The company is not currently considering a reverse stock split as a means to address the bid price deficiency [4] Group 3: Company Overview - Nexalin Technology, Inc. specializes in developing non-invasive neurostimulation products aimed at addressing mental health issues [5] - The company's devices are designed to provide relief for mental health disorders using bioelectronic medical technology, with a focus on deep brain structures [5] - The Nexalin Gen-2 15 milliamp neurostimulation device has received approval in multiple countries, including China, Brazil, Oman, and Israel [5]